COMPANY PROFILE

PIC Therapeutics

A biotechnology company focused on fundamentally changing how people treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation

Natick, United StatesFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About PIC Therapeutics

PIC Therapeutics is a biotechnology company revolutionizing cancer treatment by developing precision-based therapeutics that target cancer signaling pathways. The company focuses on selectively blocking oncogene protein production by modulating the Pre Initiation Complex (PIC) that drives mRNA translation. This approach has the potential to simultaneously modulate multiple oncogenic drivers, offering a powerful new generation of cancer treatments. PIC Therapeutics serves patients with unmet medical needs, particularly those who have developed resistance to existing therapies or face complex tumor progression. The company operates in the biotechnology and pharmaceutical markets, primarily targeting oncology. Its business model involves the research and development of small molecule precision therapeutics, which are then brought to market either through direct commercialization or partnerships with larger pharmaceutical companies. Revenue is generated through product sales, licensing agreements, and potential milestone payments from partners.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Natick, United States
Employees: 6
Open positions: None listed
Dealroom signal: 70.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Oct 2022	$35M	$140M	Advent Life Sciences · Harrington Discovery Institute · Lumira Ventures · Belinda Termeer	↗
EARLY VCOther financing	Apr 2022	$11M	$46M	Undisclosed	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

PIC Therapeutics website traffic

Latest recorded traffic for PIC Therapeutics is 730 monthly website visits, down 15.1% over the last three months. PIC Therapeutics's team grew 0% over the past year.

Latest monthly visits730 3-month web change-15.1% 1-year team growth0%

Monthly website visitsMar 2020–Dec 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHalda TherapeuticsPrecision oncology therapies targeting cancer via RIPTAC™ chimera	New Haven, United States	Acquired	40	$126M	$3B
DPDISCO PharmaceuticalsBiotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds	Cologne, Germany	Operational
RORadionetics OncologyRadionetics Oncology is a precision oncology company focusing on the discovery and development of radiopharmaceuticals	San Diego, United States	Operational
ABAtavistik BioPrecision allosteric therapeutics for oncology and rare diseases.	Cambridge, United States	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
NENeomorphDeveloping novel drugs targeting previously untreatable disease-causing proteins using molecular degradation technology	San Diego, United States	Operational
UBUBiENCEInnovative biopharmaceutical solutions targeting ubiquitin proteasome abnormalities to enhance patient quality of life	Tokyo, Japan	Operational
RTRappta TherapeuticsWorking on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A)	Helsinki, Finland	Operational